BIOMAT Database Logo BIOMAT Database Logo

Discovery of novel thienoquinoline-2-carboxamide chalcone derivatives as antiproliferative EGFR tyrosine kinase inhibitors. 2019

Mahmoud S Abdelbaset, and Mohamed Abdel-Aziz, and Mohamed Ramadan, and Mostafa H Abdelrahman, and Syed Nasir Abbas Bukhari, and Taha F S Ali, and Gamal El-Din A Abuo-Rahma
Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, 71524 Assiut, Egypt.

Novel thienoquinoline carboxamide-chalcone derivatives were prepared via the cyclization of acylated chalcones and 2-mercaptoquinoline-3-carbaldehyde in DMF with K2CO3. Thienoquinolines 9a-f, h exhibited promising antiproliferative effect against all the tested cell lines and gave a significant activity as EGFR inhibitors, with IC50 values ranging from 0.5 and 3.2 µM, and compounds 9e and 9f being the most active of the series. They also showed better activity than Erlotinib against melanoma cancer cell line A375. Moreover, compound 9f influenced pre G1 apoptosis and cell cycle arrest at G2/M phase. The binding mode of the best EGFR inhibitor 9e in the EGFR active site revealed that the thienoquinoline ring occupied the ATP-binding site while the chalcone moiety is located in the allosteric site and is responsible for the enhanced activity of these compounds.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011804 Quinolines
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D047188 Chalcones Derivatives of CHALCONE that are important intermediates in the formation of FLAVONOIDS with anti-fungal, anti-bacterial, anti-inflammatory, and anti-tumor properties. 1,3-Diphenyl-propanediones,1,3-Diphenyl-propenones,1,3-Diphenylpropanediones,1,3-Diphenylpropenones,Chalconoids,1,3 Diphenyl propanediones,1,3 Diphenyl propenones,1,3 Diphenylpropanediones,1,3 Diphenylpropenones
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Mahmoud S Abdelbaset, and Mohamed Abdel-Aziz, and Mohamed Ramadan, and Mostafa H Abdelrahman, and Syed Nasir Abbas Bukhari, and Taha F S Ali, and Gamal El-Din A Abuo-Rahma
New pyrrolidine-carboxamide derivatives as dual antiproliferative EGFR/CDK2 inhibitors.
January 2024, Chemical biology & drug design,
Mahmoud S Abdelbaset, and Mohamed Abdel-Aziz, and Mohamed Ramadan, and Mostafa H Abdelrahman, and Syed Nasir Abbas Bukhari, and Taha F S Ali, and Gamal El-Din A Abuo-Rahma
Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
August 2011, Bioorganic & medicinal chemistry,
Mahmoud S Abdelbaset, and Mohamed Abdel-Aziz, and Mohamed Ramadan, and Mostafa H Abdelrahman, and Syed Nasir Abbas Bukhari, and Taha F S Ali, and Gamal El-Din A Abuo-Rahma
Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
March 2016, Bioorganic & medicinal chemistry letters,
Mahmoud S Abdelbaset, and Mohamed Abdel-Aziz, and Mohamed Ramadan, and Mostafa H Abdelrahman, and Syed Nasir Abbas Bukhari, and Taha F S Ali, and Gamal El-Din A Abuo-Rahma
Discovery of novel quinazoline derivatives bearing semicarbazone moiety as potent EGFR kinase inhibitors.
January 2018, Computational and structural biotechnology journal,
Mahmoud S Abdelbaset, and Mohamed Abdel-Aziz, and Mohamed Ramadan, and Mostafa H Abdelrahman, and Syed Nasir Abbas Bukhari, and Taha F S Ali, and Gamal El-Din A Abuo-Rahma
Novel benzimidazole analogs as inhibitors of EGFR tyrosine kinase.
October 2012, Chemical biology & drug design,
Mahmoud S Abdelbaset, and Mohamed Abdel-Aziz, and Mohamed Ramadan, and Mostafa H Abdelrahman, and Syed Nasir Abbas Bukhari, and Taha F S Ali, and Gamal El-Din A Abuo-Rahma
Discovery of new cyanopyridine/chalcone hybrids as dual inhibitors of EGFR/BRAFV600E with promising antiproliferative properties.
April 2023, Archiv der Pharmazie,
Mahmoud S Abdelbaset, and Mohamed Abdel-Aziz, and Mohamed Ramadan, and Mostafa H Abdelrahman, and Syed Nasir Abbas Bukhari, and Taha F S Ali, and Gamal El-Din A Abuo-Rahma
Discovery of novel JAK2 and EGFR inhibitors from a series of thiazole-based chalcone derivatives.
March 2021, RSC medicinal chemistry,
Mahmoud S Abdelbaset, and Mohamed Abdel-Aziz, and Mohamed Ramadan, and Mostafa H Abdelrahman, and Syed Nasir Abbas Bukhari, and Taha F S Ali, and Gamal El-Din A Abuo-Rahma
Discovery of novel EGFR tyrosine kinase inhibitors by structure-based virtual screening.
June 2012, Bioorganic & medicinal chemistry letters,
Mahmoud S Abdelbaset, and Mohamed Abdel-Aziz, and Mohamed Ramadan, and Mostafa H Abdelrahman, and Syed Nasir Abbas Bukhari, and Taha F S Ali, and Gamal El-Din A Abuo-Rahma
Discovery of 1-Amino-1H-imidazole-5-carboxamide Derivatives as Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitors.
November 2021, Journal of medicinal chemistry,
Mahmoud S Abdelbaset, and Mohamed Abdel-Aziz, and Mohamed Ramadan, and Mostafa H Abdelrahman, and Syed Nasir Abbas Bukhari, and Taha F S Ali, and Gamal El-Din A Abuo-Rahma
Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
September 2012, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!